| 主权项 |
1. A method for treating a p62-mediated disease in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound of structural Formula I: or a pharmaceutically acceptable salt or ester thereof, wherein
Ar is an arylene or heteroarylene;R1 has a structure of: wherein W is an alkanediyl, alkenediyl, a carbonyl, or a combination thereof;X is —NR5—, wherein R5 is H or an alkyl, or —O—; andY is a hydroxyalkyl, an aminoalkyl, or a carboxylalkyl;each R2 is the same or different and has a structure of: wherein Z is —NR6—, wherein R6 is H or an alkyl, —O—, —S—, or —CH2—;Z1 is (—CH2—)m wherein m is 0 to 5, or an alkenediyl having 2 to 6 carbon atoms;Cy is a 3-8-membered cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring; andeach R4 is the same or different and is selected from hydroxy, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, or amino; and c is 0 to 5; andeach R3 is the same or different and is selected from hydrogen, hydroxy, halogen, —CN, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, amino, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or a nitro, wherein a is 0 to 5, and b is 0 to 3. |
